RANI: Rani Therapeutics Holdings, Inc. Company Value to Net Income

Corporate emblem and logo of Rani Therapeutics Holdings, Inc. (RANI)

The team led by Talat Imran at Rani Therapeutics (RANI) is developing innovative methods for transporting biologics via capsules. The business model is independent of economic cycles or seasonality, relying instead on the achievement of medical objectives, with the indicator standing at -1.90. The price trend on the GURU.Markets platform reflects a company developing R&D partnerships with industry behemoths to convert injections into an oral format.

RANI Rani Therapeutics Holdings: Price to Earnings Ratio in the range 07/04/2022 - 11/15/2026

Comprehensive metric breakdowns and analytics for Rani Therapeutics Holdings (RANI)

- price and consensus price forecast:
Stock Price Rani Therapeutics Holdings, Inc.|RANI - Consensus Target
- market capitalization information:
Market Value Rani Therapeutics Inc|RANI - Total Company Value
- balance sheet net asset value indicators:
Net Asset Value per Share Rani Therapeutics|RANI - Company Net Assets|Market Cap to Book Value Multiple ranitherapeutics.com|RANI - Company Total Assets
- company liabilities and liquidity data:
All Debt to Shareholders' Equity Ratio Rani Therapeutics|RANI - Long-Term Debt to Capital|Current Liabilities to Capital ranitherapeutics.com|RANI - Company Debts|Debt to Net Assets Ratio Rani Therapeutics Inc|RANI - Company Long-Term Debt|Company Short-Term Loans and Borrowings Rani Therapeutics|Quick Ratio ranitherapeutics.com
- business earnings and investment ratios data:
RANI - Company Net Income|Net Profit Forecast Rani Therapeutics|RANI - P/E Multiple|Market Cap to Projected Earnings Rani Therapeutics Holdings, Inc.|RANI - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation RANI|RANI - Operating profit before deduction of amortization|Earnings per share for the last four quarters Rani Therapeutics|RANI - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months ranitherapeutics.com|RANI - Earnings growth in current year|Expected net earnings per share growth next year Rani Therapeutics
- issuer revenue and sales details:
RANI - Company Revenue|Company Future Revenue Rani Therapeutics|RANI - P/S Multiple|Forward P/S Multiple Rani Therapeutics Inc
Comprehensive company analysis:Rani Therapeutics Holdings - RANI
Flagship merchandise of Rani Therapeutics Holdings, Inc.

Separating stable assets from speculative instruments requires an analysis of the market value-to-net profit ratio, which allows for an assessment of the premium paid for future growth. The licensing of the Rani Therapeutics (RANI) RaniPill platform ensures an inflow of advance payments and strengthens capital; therefore, the IFRS P/E multiple serves as an indicator of the balance between the business's fundamental value and current investor expectations regarding the sustainability of cash flows.

Analysis of competing companies

HLN: Company Value to Net Income|Price to Earnings Ratio KVUE (Kenvue Corp)|VRNA (Verona Pharma Inc.) - Company Value to Net Income|Price to Earnings Ratio Jyong Biotech Limited MENS|Ligand (LGND) - Market Cap to Earnings|AMRX: Price to Earnings Ratio|Perrigo - Market Price to Net Income Ratio|ALVO: P/E Multiple|Liquidia Technologies - Company Value to Net Income|GLPG (Galapagos N.V.) - P/E Multiple|Market Cap to Earnings anipharmaceuticals.com ANIP|Price to Earnings Ratio MannKind (MNKD)|AMPH (Amphastar Pharmaceuticals, Inc.) - Company Value to Net Income|Price to Earnings Ratio Pacira BioSciences, Inc. PCRX|P/E Multiple ARS Corp SPRY|Theravance Biopharma - P/E Multiple|Market Cap to Net Income Ratio Aquestive Therapeutics, Inc. (AQST)|scPharmaceuticals (SCPH) - Price to Earnings Ratio|Price to Earnings Ratio Tectonic Therapeutic, Inc.|TNXP (Tonix Pharmaceuticals Holding) - P/E Multiple|Price to Earnings Multiple SXTC (China SXT Pharmaceuticals)|P/E Multiple EPRX|P/E Multiple bioharvest.com (BHST)|Price to Earnings Ratio Invizyne Technologies EXOZ|ORMP: Price to Earnings Multiple|ENTX: Price to Earnings Ratio|HYFT: Price to Earnings Ratio|ABVC BioPharma Inc. (ABVC) - Price to Earnings Ratio|cumberlandpharma.com (CPIX) - P/E Multiple|QNTM (Quantum BioPharma) - P/E Multiple|FGEN: Company Value to Net Income|P/E Multiple TELO|SNYR (Synergy CHC) - Company Value to Net Income|Price to Earnings Ratio Rallybio RLYB|Lexaria Bioscience (LEXX) - Market Cap to Earnings|PULM - Price to Earnings Ratio|Business Payback Period Pheton Holdings PTHL|APM (Aptorum) - Price to Earnings Ratio|Lyra Therapeutics, Inc. (LYRA) - P/E Multiple|IBO (impactbiomedinc.com) - P/E Multiple|TNFA (TNF Pharmaceuticals) - Market Price to Net Income Ratio|Price to Earnings Ratio cbdmd.com (YCBD)|Business Payback Period PainReform Ltd|P/E Multiple CYTO (Altamira Therapeutics Ltd.)|Lipella Pharmaceuticals (LIPO) - Market Cap to Earnings|OPTN - Price to Earnings Ratio|Pieris Pharmaceuticals - Market Price to Net Income Ratio|PROC (Procaps Group) - Price to Earnings Ratio|PTPI - Business Payback Period|Price to Earnings Ratio Qilian International Holding Group Limited|SLRN: Company Value to Net Income|Price to Earnings Ratio TFFP (TFF Pharma)